NRx Pharmaceuticals (NRXP) to Release Earnings on Friday

NRx Pharmaceuticals (NASDAQ:NRXP) is expected to post its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Stock Performance

Shares of NRx Pharmaceuticals stock opened at $1.94 on Wednesday. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $6.01. The company has a fifty day moving average of $2.50 and a 200-day moving average of $2.05. The stock has a market capitalization of $32.82 million, a price-to-earnings ratio of -0.91 and a beta of 1.22.

Analyst Ratings Changes

Several analysts have issued reports on NRXP shares. D. Boral Capital restated a “buy” rating and set a $31.00 price target on shares of NRx Pharmaceuticals in a research report on Monday. HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of NRx Pharmaceuticals in a report on Thursday, March 20th.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.